Selection of blockbuster announcements

1、Fast Dog Taxi (temporary Code) (810206.HK) $It is proposed to issue 31.2 million shares with a share price of HK $21.50 per share.

The company plans to issue 31.2 million shares from June 14 to June 17, 2022, of which 10 per cent are sold in Hong Kong, 90 per cent in international sales and 15 per cent in over-allotment options. The offering price will be HK $21.50 per offer share and 200 shares per share, which is expected to be listed on June 24, 2022.

2、$Junshi creature (01877.HK) $The trial application of the fourth generation EGFR inhibitor WJ13404 tablets has been approved

According to Junshi Biological announcement, Suzhou Junjing Biopharmaceutical Technology Co., Ltd., a subsidiary of the company, received a notice of approval for Drug Clinical Trials approved and issued by the State Drug Administration, and the application for clinical trials of the fourth generation EGFR inhibitor WJ13404 tablets (project code "JS113") was approved.

3、$Fuhong Hanlin (02696.HK) $Enter into license and supply agreement with Organon for HLX11 and HLX14

Fuhong Hanlin announced that the company signed a "license and supply Agreement" with Organon. Granted to Organon and its holding subsidiaries for the exclusive development and commercialization (including but not limited to imports, of HLX11 (recombinant anti-HER2 domain II humanized monoclonal antibody injection) and HLX14 (recombinant anti-RANKL whole-person monoclonal antibody injection) in the region (i.e. worldwide except Chinese mainland and Hong Kong, Macao and Taiwan) and in the field (i.e., for each licensed bioanalogue approved for market in each country). License of sales, distribution, etc.) and other rights related thereto.

4、$clover organism-B (02197.HK) $SCB-2019 completed the first batch of subjects' vaccination in the III phase trial of heterologous COVID-19 strengthening needle.

Clover Biological-B announcement, an evaluation of clover biological candidate vaccine SCB-2019 (CpG 1018 ╱ aluminum adjuvant) as the first batch of subjects in the phase III study of COVID-19 to enhance the safety and immunogenicity of needles. The subjects were previously vaccinated with two doses of Kelaifu TM (inactivated Kexing vaccine), Comirnaty ®(Pfizer Inc mRNA vaccine) or Vaxzevria ®(AstraZeneca PLC virus vector vaccine).

5、$Byd Company Limited (01211.HK) $On June 13th, it spent 1.035 billion yuan to buy back 2.9541 million A shares.

Byd Company Limited announcement shows that on June 13, it spent 1.035 billion yuan to buy back 2.95 million A-shares, with a repurchase price range of 344.33 yuan to 358.58 yuan.

Listing of new shares

Fast Dog Taxi (02246) plans to issue 31.2 million shares at a price of HK $21.50 per share.

Operation data

Jenny Virgil (02199) expects annual net profit to grow by no less than 300% year-on-year, and sales are expected to maintain growth in fiscal year 2023

China Life Insurance Company Limited (02628): from January to May, the original premium income of 379.2 billion yuan decreased by 1.86% compared with the same period last year.

New China Life Insurance (01336) the premium income from January to May was 86.779 billion yuan, an increase of 4.97% over the same period last year.

China Resources Land (01109): cumulative contract sales of 81.35 billion yuan in 2022

Increase and decrease holdings

China Communications Construction (01800): the controlling shareholder increases the holding of H shares of the company by 1%

China International Capital Corporation (03908): Haier Jinying plans to reduce its holdings of no more than 135 million A shares of the company.

Merger and acquisition and sale

Haitong Hengxin (01905) plans to sell basic assets for 996 million yuan.

Sichuan Chengdu-Chongqing Expressway (00107) plans to purchase charging station assets no more than 85.84 million yuan.

Additional rights issue

China Water Group (01129) proposes to raise about HK $166 million through "2 rights issues and 1 rights issue".

China Tiangong Holdings (00428) intends to discount about 19.3% to raise HK $18.6 million by placing 86.334 million shares.

Investment and operation

INNOVENT BIO (01801): Dayutong ®(bevacizumab injection) approved in Indonesia

IDG Energy Investment (00650) plans to acquire two solar companies for HK $412 million

Junshi Bio (01877): the application for the fourth generation EGFR inhibitor WJ13404 tablets has been approved.

Fu Hong Hanlin (02696): enter into a license and supply agreement with Organon for HLX11 and HLX14

Man Wah (01999): it is possible to spin off Ruimai Technology and list on the exchange of Chinese mainland

Jedi Group (08313) Joint Venture successfully bid for the proposed condominium development project at 8 Bukit Padu West Street, Singapore.

Binhai Investment (02886) won Bohua Wynn Thermal Coal Combustion Project

CSPC Pharmaceutical (01093): "Praxol Hydrochloride sustained release tablets" was approved by drug registration.

INNOVENT BIO (01801): the State Drug Administration accepts the application for listing of the new drug of Toleizumab injection independently developed by INNOVENT BIO.

China Communications Construction (01800) shareholding company was ruled by the court to accept the reorganization

Clover organism-B (02197): SCB-2019 as the III phase trial of heterologous COVID-19 strengthening needle completed the first batch of subjects' vaccination.

Repurchase cancellation

Byd Company Limited (01211) spent 1.035 billion yuan to buy back 2.9541 million A shares on June 13.

China Vanke (02202) spent 170 million yuan to buy back 9.72 million A shares on June 13.

Guotai Junan International (01788) spent HK $1.7838 million to buy back 2.049 million shares on June 13th

HSBC Holdings PLC (00005) spent HK $79.303 million to buy back 1.584 million shares on June 10.

Ming Yuan Cloud Group (00909) spent HK $10.01 million to buy back 964000 shares on June 13th

Sinotrans (00598) spent HK $2.922 million to buy back 1.314 million shares on June 13.

CK Asset (01113) spent HK $23.287 million to buy back 452500 shares on June 13th

China Conch Venture (00586) spent HK $8.06 million to buy back 467000 shares on June 13th

AIA Group Limited (01299) spent HK $157 million to buy back 2 million shares on June 13th

Fangda Holdings (01521) spent HK $6.158 million to buy back 2 million shares on June 13.

Innovation Qizhi (02121) spent HK $2.1991 million to buy back 106800 shares on June 13th

Equity incentive

Yongsheng Medical (01612) granted 13.3923 million share options

Dali Foods Group (03799): purchase a total of 219.6 million shares under the share incentive scheme